Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,181.01 -6.69 (-0.13%) Dow
38,899.61 +15.35 (+0.04%) Nasdaq
16,290.44 -42.11 (-0.26%) Bitcoin USD
62,353.63 -1,042.39 (-1.64%) CMC Crypto 200
1,325.78 +31.11 (+2.40%)
AstraZeneca PLC (AZN)
| Previous close | 76.32 |
| Open | 76.79 |
| Bid | 76.99 x 300 |
| Ask | 77.09 x 300 |
| Day's range | 76.62 - 77.11 |
| 52-week range | 60.47 - 77.11 |
| Volume | |
| Avg. volume | 6,202,893 |
| Market cap | 238.845B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 38.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.45 (1.90%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- GlobeNewswire
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (LSE/STO/Nasda
- Business Wire
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).
- Business Wire
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as
